Medivation (MDVN +1.2%) gains today after presenting data for its monotherapy enzalutamide,...

|By:, SA News Editor

Medivation (MDVN +1.2%) gains today after presenting data for its monotherapy enzalutamide, showing it's treatment on prostate cancer has positive results. The study showed that the treatment increased serum testosterone by a mean of 114% at week 25 as compared to its baseline, and the median change in PSA was -99.6%.